Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAROT: Scalp Hair Density Changes in Breast Cancer Patients Receiving Trastuzumab Deruxtecan
jRCTs031240415Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of trastuzumab deruxtecan in breast cancer and Breast cancer recurrence (rBC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in Hair Density. Started Dec 2024; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancerBreast cancer recurrence (rBC)
Beyond the preview
Go deeper on jRCTs031240415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240415.